Machine-intelligence design yields selective synthetic COX-1 inhibitors from a marine natural-product template
Using Marinopyrrole A as a template, an automated design workflow generated and synthesized new natural-product-inspired molecules; target-prediction software pointed to cyclooxygenases. In biochemical assays, synthetic mimetics 2 and 2a inhibited COX-1 at 0.10 and 0.16 μM, respectively, and compound 2a was crystallographically observed bound to COX-1. Human platelet assays also showed inhibition.
Technology: DOGS rule-based de novo molecule construction and CATS molecular-similarity ranking, coupled with SPiDER self-organizing-map machine-learning target prediction
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In biochemical assays, synthetic mimetics 2 and 2a inhibited COX-1 at 0.10 and 0.16 μM, respectively, and compound 2a was crystallographically observed bound to COX-1.
- Still unknown: The study tests a small number of designed molecules; automated structure generation was rule-based and similarity-driven rather than a trained generative neural model. The COX-1 effects were biochemical/platelet assays, not clinical effects; the platelet IC50s for 2, 2a, 2b were 9, 13 and 56 nM, but COX-2 inhibition occurred at higher concentrations and selectivity varies by assay. Do not call these approved drugs or imply therapeutic benefit.
- AI role: DOGS algorithmically generated natural-product-inspired structures and suggested synthetic routes; CATS ranked candidates by pharmacophore similarity. SPiDER's cascaded self-organizing-map models predicted molecular target families, including COX. Experimental target assays confirmed the previously unrecognized COX-1 activity of selected synthetic compounds, with crystallographic confirmation for compound 2a.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8373093/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 84 of works of the same type, year and subfield (OpenAlex work metrics, 31 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.